Mass General Brigham’s Maze Therapeutics MAZE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.79M Buy
249,636
+9,642
+4% +$268K 1.49% 6
2026
Q2
$7.16M Hold
239,994
– – 1.98% 5
2026
Q1
$7.16M Hold
239,994
– – 1.53% 5
2025
Q4
$9.9M Buy
+239,994
New +$8.25M 1.23% 4

Other funds holding MAZE

Mass General Brigham's MAZE Position: Q3 2026 in Review

Mass General Brigham increased its Maze Therapeutics (MAZE) stake by 4% in Q3 2026, buying an estimated $268K and bringing the position to 249,636 shares worth $6.79M. The position accounts for 1.49% of the portfolio, ranked #6.

Mass General Brigham first reported a position in MAZE in Q4 2025 and has held it in 4 quarters since. The position peaked at $9.9M in Q4 2025. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Mass General Brigham held 249,636 shares of Maze Therapeutics worth $6.79M as of Q3 2026.
  • Mass General Brigham bought 9,642 Maze Therapeutics shares in Q3 2026, an estimated $268K.
  • Maze Therapeutics made up 1.49% of Mass General Brigham's portfolio in Q3 2026, its #6 holding.
  • Mass General Brigham first reported a position in Maze Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Mass General Brigham's Maze Therapeutics position peaked at $9.9M in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Mass General Brigham's 13F filing for Q3 2026, filed 3 Nov 2026.